Liposomal Superoxide Dismutase
Polymun has encapsulated recombinant human Cu/Zn superoxide dismutase (SOD) in liposomes using its proprietary technology. The liposomal formulation enables topical application of SOD as well as application by inhalation. As a scavenger of free oxygen radicals, SOD has high potential for the treatment of pathologic conditions connected with oxidative stress free of any adverse effects.
Polymun has evaluated the transdermal application of Lipoxysan™ in patients suffering from Induratio Penis Plastica (IPP, also Peyronie′s disease) in phase II and III clinical trials. The studies were conducted at three centres in Austria under the leadership of Claus Riedl, M.D. (claus.riedl@thermenklinikum-baden.at) and resulted in significant and rapid decrease of pain and amelioration of the other symptoms of IPP. Lipoxysan™ treatment was efficacious, free of side effects and convenient thus leading to high patient satisfaction. Details to the studies can be found in our publications "Pilot Study on Liposomal Recombinant Human Superoxide Dismutase for the Treatment of Peyronie′s Disease" and "Liposomal Recombinant Human Superoxide Dismutase for the Treatment of Peyronie′s Disease: A Randomized Placebo-Controlled Double-Blind Prospective Clinical Study".
Lipoxysan™ is also tested for the treatment of inflammatory skin disorders and chronic skin ulcers. Beneficial effects of Lipoxysan™ therapy in wound healing were obtained in animal models of thermal lesions (Vorauer-Uhl et al. 2002).
Lipoxysan™ is believed to have high therapeutic potential in dermatological conditions since increased production of reactive oxygen species (ROS) was connected with various inflammatory skin disorders.
As oxidative stress induced by UV-light, cigarette smoke, air pollution, ozone, and chemicals is believed to trigger premature skin aging, there is a strong rationale to use liposomal SOD in cosmetic anti-aging products. All ingredients of the liposomal SOD are on the inventory of ingredients used in cosmetic products (Section I of the Annex to Commission Decision 96/335/EC).
In May 2015, Polymun entered into a license an development agreement with SCARLETRED Holding GmbH for development and marketing of SOD for several indications.
